Systematic Review and Meta-Analysis

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Short title: Gynecologic Cancer Patients With The Covid-19 Infection

I Gde Sastra Winata[1], Januar Simatupang[2] , Arie A Polim[3,4], Yakob Togar[2], Advenny Elisabeth Tondang[2]

[1] Faculty of Medicine, Department of Obstetrics and Gynecology, Udayana University, Denpasar, Bali, Indonesia.

[2] Faculty of Medicine, Department of Obstetrics and Gynecology, Christian University of Indonesia, Jakarta, Indonesia.

[3] Department of Obstetrics and Gynecology, School of Medicine and Health Sciences, Atmajaya Catholic University of Indonesia, Jakarta, Indonesia

[4] Morula IVF , Jakarta, Indonesia

ORCID ID of All Authors :

I Gde Sastra Winata : https://orcid.org/**0000-0001-6142-960X**
Januar Simatupang : https://orcid.org/**0000-0002-8952-7671**

Arie A Polim : https://orcid.org/**0000-0001-5876-4968**

Yakob Togar : https://orcid.org/**0000-0001-6554-6379**

Advenny Elisabeth Tondang : https://orcid.org/**0000-0002-7703-4220**

Acknowledgments: We thank the staff of Gynecology Oncology (Sanglah Hospital, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia), staff of Reproductive Endocrinology and Infertility (Morula IVF), (School of Medicine and Health Sciences, Atmajaya Catholic University of Indonesia, Jakarta, Indonesia), and staff of Department of Obstetrics and Gynecology (UKI Hospital, Faculty of Medicine, Christian University of Indonesia, Jakarta, Indonesia) to make this research collaboration possible.

Correspondence to: Yakob Togar, MD. Jl.Haji Achyar No 10. Duren Sawit, Jakarta 13440 , Indonesia.

vincentharlingcute@gmail.com , vincent_harlling@yahoo.com . +6281298003785

Disclaimers: None Declared.

Abstract

Objective: Cancer is a comorbidity that leads to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to yield evidence of adverse outcomes of Covid-19 in gynecologic cancer.

Methods: Searches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool is used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557).

Results: We accepted 51 studies (1991 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.90, *p* 0.005). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, *p* 0.01), (OR 0.52, CI 0.44-0.62, *p* <0.0001), (OR 0.26, CI 0.10-0.67 *p* 0.005), (OR 0.63, CI 0.47-0.83, *p* 0.001) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.50, CI 1.20-1.88, *p* 0.0004), (OR 11.83, CI 8.20-17.07, *p* <0.0001), (OR 2.98, CI 2.23-3.98, *p* <0.0001) respectively.

Conclusion: Gynecologic cancer has higher Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer has fewer Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. These findings may aid health policies and services during the ongoing global pandemic.

Keywords: COVID-19, Critical care outcome, Female genital neoplasms, Hospitalization, Morbidity, Mortality.

INTRODUCTION

The Covid-19 pandemic has changed the way of health care providers around the world manage care provided to their patients. The pandemic has also proven to shift the attitude of standard practice and procedure between providers and patients, for example, to reduce gynecologic cancer patients visiting the hospital as possible because the risk of getting infected with Covid-19 is increased regarding their comorbidities.[1] Despite this circumstance, gynecologic cancer patients is still often required to perform routine hospital visits for treatments or other medical procedures under guidance made by gynecological cancer societies during the Covid-19 pandemic.[2] The cancer incidence and mortality are still increasing around the world. According to Global Cancer Statistic: 2020 for gynecologic cancer, there are 604.127, 417.367, 313.959, 45.240, and 17.908 new cases of cancer of the cervix uteri, corpus uteri, ovary, vulva, and vagina respectively.[3] Most concerns are coming from these patients about how they may proceed to seek or continue their cancer treatment and surveillance during the Covid-19 pandemic time whether they should continue or delay.[4] Studies are showing various results on increased mortality and severity among cancer patients infected with Covid-19. Systematic review and meta-analysis studying the outcome of cancer patients with Covid-19 show 2.1-4% proportion of cancer patients among those infected with Covid-19, additionally compared to non-cancer with Covid-19 greater amount of mortality and severity are observed in cancer population with Covid-19.[5-7] However studies and data on the outcome of gynecologic cancer patients with Covid-19 are still lacking. We are now entering the third year of the Covid-19 pandemic after the first confirmed case was announced in December 2019 in Wuhan, Hubei Province, The People's Republic of China. Several SARS-CoV-2 variants of concerns listed by WHO (World Health Organization) pose challenges in mitigating the pandemic as these variants often increase transmission rate and severity.[8] The world has been experiencing a wave of active case surges by these variants and on 26 November 2021 the WHO designated the variant Omicron (B.1.1.529) as an addition to the list.[9] Thus we attempt to review the literature and quantify the effect of the SARS-Cov-2/Covid-19 infection among gynecologic cancer patients whether the risk of infection, hospitalization, severity, and mortality are increased than non-gynecologic cancer population.

MATERIALS AND METHODS

We conducted this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses/PRISMA statement.[10] This study and its protocol were registered to PROSPERO (CRD42021256557).

Eligibility Criteria

We took into consideration of studies with observational cohort studies, case-control, cross-sectional, case report, and case series designs that evaluate the outcome of gynecologic cancer patients infected with Covid-19 from the year 2019. Each study ought to report Covid-19 associated infection, hospital admission, mortality, severity, or admission to the ICU provided both in the main result or supplementary data. We exclude studies other than the English language, reviews or guidelines, and inconceivable results of the sought outcome.

Comparator(s) / Control.

Non-cancer Covid-19 patients, non-Covid-19 cancer patients, other cancer types / non-gynecological cancer with Covid-19.

Database and Literature Search

Study articles were systematically searched through PubMed/Medline, ScienceDirect, Google Scholar, and medRxiv. Relevant articles had been screened from 24 July 2021 to 19 February 2022. Reference searches from retrieved articles citation lists were identified if any were needed. Boolean operators technique used for Pubmed/Medline search with ("COVID-19" or "2019-nCoV" or "SARS-CoV" or SARSCOV2 or 2019-nCov or "2019 coronavirus" or covid19) AND (gynecology or gynaecology) AND (tumor or malignancy or cancer) AND (outcomes or outcome) AND (gyn* tum* or gyn *malign* or gyn* cancer) AND (cancer surgery or oncolog* surger*) AND (brachytherapy or radiotherapy). We used “Gynecologic cancer AND Covid-19” with Google Scholar, Science Direct, and medRxiv. Two authors separately handled the literature search. Findings were accumulated and stored in Mendeley and Zotero for management and automated duplicate identification. Thorough stepwise screening from title and abstract was then conducted to determine possible article inclusion. Potentially eligible studies were then evaluated for in-depth full-text review. Each author would consult senior authors to resolve any differences found during the literature's selection process.

Data Extraction and Quality Assessment

Two authors extracted data independently and stored them in The Microsoft Excel spreadsheet. Data is then discussed for an agreement. Name of authors, year of publication, country, type of studies, study period, number of patients, comparators, and target conditions was collected. The NOS / Newcastle-Ottawa Scale will be used by authors to assess the quality of the cohort and case-control study, and The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for an analytical cross-sectional study.[11] Two authors performed the assessment and the results were discussed with the first author.

Meta-Analysis Outcome

The main outcome of interest was Covid-19 mortality and severity. Covid-19 severity is defined as either ICU admission, ARDS, or need for mechanical ventilation. Covid-19 infection and hospitalization were decided as secondary outcomes.

Data Analysis & Synthesis

We performed data analysis mainly using Review Manager 5.4.1 (RevMan 5.4.1) by Cochrane collaboration.[12] Additional synthesis if any were needed then performed with STATA-16. We synthesized the dichotomous outcome from each study with an odds ratio (OR). The random-effects model (DerSimonian and Laird) was used to present pooled OR with 95% CI (Confidence Interval) and the result of overall effect (*p*). We addressed the presence of heterogeneity with I^2 as 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity.[13] We performed subgroup analysis by age, gender, other comorbidities status, cancer type, cancer stage, presence of metastatic disease, and active cancer treatment. Sensitivity analysis would be performed by dividing multi-center/single-center studies and removing/including the latest study period if concerns were raised of patients population duplication thus we could present robust pooled evidence.[14]

RESULTS

A total of 51 studies involving the Covid-19 positive population, among them are 1991 gynecologic cancer patients, 221465 non-cancer patients, and 28138 other cancer type patients. 3717078 cancer patients were found to be Covid-19 free. Study selection and summary of included studies were presented in **Figure 1** and **Table S1**. The risk of bias in each study was shown in **Fig. S1** and **Fig. S2**.

Gynecologic Cancer VS Other Cancer

Covid-19 infection was equivalent between gynecologic cancer and other cancer gathered from 8 studies (OR 1.02, CI 0.84-1.22, *p* 0.87, I^2 57%) **Fig. S3**.[33,39,50,51,55,56] Gynecologic cancer had fewer Covid-19 associated death compared to other cancer according to 30 studies (OR 0.82, CI 0.71-0.94, *p* 0.006, I^2 0%) **Figure 2**.[18-20,24-28,30,32,37,39-42,45,46,48,50,52-55,57,58,60] Covid-19 associated severity was not significant from 6 studies between gynecologic cancer and other cancer (OR 0.56, CI 0.30-1.03, *p* 0.06, I^2 0%) **Fig. S4**.[24,25,32,53,54,60] Data from 2 studies also showed non significance from Covid-19 hospitalization in gynecologic cancer patients than other cancer (OR 0.73, CI 0.50-1.06, *p* 0.10, I^2 82%) **Fig. S5**.[30,50]

Gynecologic Cancer VS Non-Cancer

Covid-19 infection among gynecologic cancer and non cancer population was not significant from 6 studies (OR 1.55, CI 0.81-2.95, *p* 0.18, I^2 90%) **Fig. S6**.[35,39,50,56,59] Data from 11 studies revealed death from Covid-19 was higher

in gynecologic cancer than non cancer patients (OR 2.98, CI 2.23-3.98, p <0.0001, I^2 30%) **Figure 3**.[18,20,24,27,38,39,42,50,54] However, severe Covid-19 was not significant in gynecologic cancer than non cancer patients from 2 studies (OR 1.85, CI 0.77-4.44, p 0.17, I^2 0%) **Fig. S7**.[24,54]

Gynecologic Cancer VS Non-Covid

Data represented from 5 studies revealed that gynecologic cancer patients were experiencing higher Covid-19 associated death in comparison to other cancer patients without Covid-19 infection (OR 11.83, CI 8.20-17.07, p <0.0001, I^2 5%) **Figure 4.**[16,39,44,50]

Cancer Treatment Group

We analysed effect of active cancer treatment comprising SACT(Systemic anti cancer therapy), radiotherapy, cancer surgery, and hormonal therapy. Data from 9 studies showed among those who receive active cancer treatment, Covid-19 infection was not significant in gynecologic cancer patients compared to other cancer (OR 0.75, CI 0.55-1.02, p 0.07, I^2 0%) **Fig. S8**.[15,17,23,29,31,34,43,47,61] Covid-19 death was not significant among cancer treatment between gynecologic cancer and other cancer gathered from 9 studies (OR 0.86, CI 0.41-1.78, p 0.68, I^2 0%) **Fig. S9**.[15,21,24,25,32,38,44,47,49] Severe Covid-19 was not significant in gynecologic cancer than other cancer, both who were receiving active cancer treatment according to 6 studies (OR 0.63, CI 0.18-2.25, p 0.48, I^2 18%) **Fig. S10**.[24,25,32,44,47,60] According to 5 studies the Covid-19 death was comparable in gynecologic cancer with active cancer treatment compared to who were not receiving cancer treatment (OR 1.06, CI 0.57-1.98, p 0.86, I^2 0%) **Fig. S11**.[22,24,25,32,36] Lastly, 5 studies showed severity from Covid-19 was not significant in gynecologic cancer who had active cancer treatment than who had none (OR 0.45, CI 0.17-1.20, p 0.11, I^2 26%) **Fig. S12.**[24,25,32,36,60]

Cancer Stage and Metastatic Cancer

2 studies were available for cancer stage analysis.[24,25] Overall adverse Covid-19 events (infection/hospitalization/severity/death) showed no significance between stage I-II gynecologic cancer against stage III-IV other cancer, stage III-IV gynecologic cancer against stage I-II other cancer, and among all cancer patients who had stage III-IV cancer (OR 0.78, CI 0.04-16.18, p 0.88, I^2 67%), (OR 0.48, CI 0.15-1.53, p 0.21, I^2 0%), (OR 0.59, CI 0.22-1.58, p 0.29, I^2 0%) respectively **Fig. S13-S15**. 3 studies also showed no significance on Covid-19 adverse events between stage III-IV and I-II gynecologic cancer (OR 0.72, CI 0.39-1.33, p 0.29, I^2 0%) **Fig. S16.**[24,25,36]

3 studies provided data on metastatic status.[20,25,39] Gynecologic cancer with metastasis was having increased Covid-19 death than those with localized cancer (OR 1.53, CI 1.06-2.21, p 0.02, I^2 0%) **Figure 5**. Contrary,

among those who had metastatic diseases, Covid-19 death was not significant between gynecologic cancer compared to other cancer (OR 0.77, CI 0.54-1.11, *p* 0.17, I^2 0%) **Fig. S17**.

Gynecologic cancer VS Lung Cancer

13 studies provided data on Covid-19 infectivity, infection was not significant in gynecologic cancer than lung cancer (OR 0.86, CI 0.61-1.20, *p* 0.37, I^2 73%) **Fig. S18**.[15,17,23,29,33,39,43,50,51,56,61] Data from 30 studies revealed that gynecologic cancer had fewer Covid-19 death than lung cancer patients (OR 0.52, CI 0.44-.062, *p* <0.0001, I^2 0%) **Figure 6A**.[15,18-21,24-28,30,32,37,39,40-42,45,46,48-50,52-54,57,58] Data from 6 studies showed that gynecologic cancer was having less severity from Covid-19 than lung cancer (OR 0.36, CI 0.16-0.80, *p* 0.01, I^2 0%) **Figure 6B**.[24,25,32,53,54,60] Lastly, 2 studies reported fewer hospitalization associated with Covid-19 in gynecologic cancer than lung cancer (OR 0.54, CI 0.40-0.73, *p* <0.0001, I^2 0%) **Figure 6C**.[17,30]

Gynecologic cancer VS Breast Cancer

Data from 13 studies showed gynecologic cancer and breast cancer were equivalent on having Covid-19 infection (OR 1.05, CI 0.94-1.17, *p* 0.37, I^2 7%) **Fig. S19**.[15,17,29,33,39,43,47,50,51,56,61] Interestingly from 25 studies, gynecologic cancer was experiencing higher Covid-19 death compared to breast cancer patients (OR 1.50, CI 1.20-1.88, *p* 0.0004, I^2 19%) **Figure 7A**.[15,18-20,25-28,30,32,37,39-42,45,48-50,53,54,57,58] Covid-19 severity was not significant from 7 studies between gynecologic cancer and breast cancer (OR 0.83, CI 0.40-1.72, *p* 0.62, I^2 0%) **Fig. S20**.[24,25,32,47,53,54,60] Lastly, data from 2 studies showed gynecologic cancer was experiencing higher hospitalization from Covid-19 compared to breast cancer (OR 1.52, CI 1.18-1.96, *p* 0.001, I^2 0%) **Figure 7B**.[17,30]

Gynecologic cancer VS Hematologic Cancer

Data available from 8 studies revealed gynecologic cancer was having less infection of Covid-19 compared to hematologic cancer patients (OR 0.71, CI 0.56-0.90, *p* 0.005, I^2 68%) **Figure 8A**.[15,33,39,50,51,56] Data also showed that gynecologic cancer was experiencing fewer Covid-19 death compared to hematologic cancer from 24 studies (OR 0.63, CI 0.47-0.83, *p* 0.001, I^2 46%) **Figure 8B**.[15,19,20,24-28,30,32,37,39,40,42,46,48-50,52,54,58] Lastly, 4 studies also showed that gynecologic cancer was having less severity from Covid-19 compared to hematologic cancer (OR 0.26, CI 0.10-0.67, *p* 0.005, I^2 0%) **Figure 8C**.[24,25,32,54]

Gynecologic Cancer VS Men

Based on 10 studies available for synthesis, there was no significance on Covid-19 infection between gynecologic cancer population and men with cancer (OR 0.58, CI 0.27-1.22, *p* 0.15, I^2 94%) **Fig. S21**.[17,23,29,39,43,51,56,61] Compared to men with cancer and gynecologic cancer patients, the Covid-19 associated death retrieved from 23 studies showed no significance (OR 0.75, CI 0.54-1.05, *p* 0.09, I^2 23%) **Fig. S22**.[15,18,21,24,25,27,28,30,32,37,39-42,46,49,52,53,57,58]

According to 6 studies, severe Covid-19 was higher in men with cancer compared to gynecologic cancer patients (OR 0.47, CI 0.25-0.88, *p* 0.02, I^2 0%) **Figure 9A**.[24,25,32,53,54,60] Hospitalization from Covid-19 was also higher in men with cancer compared to gynecologic cancer patients synthesized from 2 studies (OR 0.71, CI 0.56-0.89, *p* 0.004, I^2 0%) **Figure 9B**.[17,30]

Age Stratification

Data from 4 studies showed that among the gynecologic cancer population, those who were >65 compared to <65 years of age had comparable overall adverse Covid-19 outcomes (infection/hospitalization/severity/death), (OR 1.13, CI 0.48-2.62, *p* 0.78, I^2 14%) **Fig. S23**.[16,22,24,25] We performed a pairwise comparison of gynecologic cancer with <65 years old against other cancer with >65 years old, and gynecologic cancer with >65 years old against other cancer with <65 years old.[24,25,60] Covid-19 adverse outcome was seen lower in <65 years old gynecologic cancer than >65 years old other cancer population (OR 0.16, CI 0.06-0.47, *p* 0.0007, I^2 0%) **Figure 10**. Contrary, there was an equivalent Covid-19 adverse outcome between gynecologic cancer with >65 years old and other cancer with <65 years old (OR 1.08, CI 0.36-3.26, *p* 0.89, I^2 0%) **Fig. S24**.

Comorbidities

Cancer is a comorbidity, aside from that we tried to analyze other comorbidities (Hypertension, diabetes, cardiovascular disease, pulmonary disease, renal disease, liver disease, immune disease,metabolic-endocrine disease) present within the cancer population. Among those with comorbidities, gynecologic cancer had few adverse Covid-19 outcomes than other cancer populations according to 4 studies (OR 0.31, CI 0.12-082, *p* 0.02, I^2 0%) **Figure 11**.[21,24,25,60] 5 studies showed there was no significant adverse Covid-19 outcome between gynecologic cancer patients with comorbidities against no comorbidities (OR 2.34, CI 0.59-9.79, *p* 0.24, I^2 79%) **Fig. S25**.[16,22,24,25,36] Gynecologic cancer without comorbidities against other cancer with comorbidities had no significant adverse Covid-19 outcome, according to 3 studies (OR 0.29, CI 0.04-2.22, *p* 0.23, I^2 56%) **Fig. S26**.[24,25,60] Gynecologic cancer with comorbidities against other cancer without comorbidities also showed no significant adverse Covid-19 outcome, according to 4 studies (OR 0.61, CI 0.22-1.72, *p* 0.35, I^2 0%) **Fig. S27**.[21,24,25,60]

Sensitivity Analysis

We performed sensitivity analysis by reproducing each outcome synthesis to pre-specified single center to multi-center studies, furthermore excluding overlapped study periods associated with its study centers thus only one center with the most recent study period was included in **Table S2**. After exclusion of 3 studies, a difference of significance was found in severe Coivd-19 between gynecologic cancer and cancer men population

(OR 0.47, CI 0.19-1.17, *p* 0.10, I^2 0%)[25,32,53] Aside from that, the remainder of calculated OR from reproducing each outcome synthesis by exclusion were within good accordance.

Publication Bias

We found no publication bias within our included studies though at first, we identified an asymmetrical funnel plot; it was caused solely by heterogeneity nonetheless (**Fig. S28-31)**. After subgroup identification, the funnel plow was corrected and the calculated Egger & Begg's test for overall Covid death, severity, and hospitalization were *p* 0.15 and *p* 1.6. For data associated with Covid-19 infection, the values were *p* 0.17 and *p* 1.87.

DISCUSSION

We believe this is the first comprehensive meta-analysis with a large population regarding the outcome of Covid-19 on the gynecologic cancer population. With the 1991 Covid-19 positive gynecologic cancer, we hope we provide new insight into how the global pandemic is affecting practice and services affecting gynecologic cancer. Several meta-analyses showed the prevalence of cancer with Covid-19 infection was 2-4%, Covid-19 mortality also higher in the cancer patients cohort.[5-7,62-66] In this meta-analysis gynecologic cancer patients are at increased risk of Covid-19 death compared to the non-cancer population (OR 2.98, CI 2.23-3.98, *p* <0.0001, I^2 30%), most studies also support this finding by providing evidence of greater Covid-19 adverse outcome in cancer patients.[5-7,62-66] Contrary to the "*N3C*" multicenter study from the United States, our result present a significant increased of death in gynecologic cancer with Covid-19 than other cancer types without Covid-19 (OR 11.83, CI 8.20-17.07, *p* <0.0001, I^2 5%).[67] Our finding shows gynecologic cancer with metastatic disease has an increased Covid-19 death compared to those whose cancer is localized (OR 1.53, CI 1.06-2.21, *p* 0.02, I^2 0%), most studies also report identical outcomes to ours.[66,68,69] Our analysis also shows gynecologic cancer is associated with higher Covid-19 death and hospitalization compared to breast cancer patients (OR 1.50, CI 1.20-1.88, *p* 0.0004, I^2 19%), (OR 1.52, CI 1.18-1.96, *p* 0.001, I^2 0%) respectively. Other meta-analyses, as well as studies done by "*CCC19*" and the "*N3C*" also supported this finding.[63,67,68] Our analysis present that gynecologic cancer patients have lower Covid-19 death compared to overall other cancer types (OR 0.82, CI 0.71-0.94, *p* 0.006, I^2 0%), further analysis shows that gynecologic cancer patients with Covid-19 have fewer adverse outcome compared to Covid-19 lung and hematologic cancer. Our findings are (OR 0.52, CI 0.44-.062, *p* <0.0001, I^2 0%), (OR 0.36, CI 0.16-0.80, *p* 0.01, I^2 0%), (OR 0.54, CI 0.40-0.73, *p* <0.0001, I^2 0%) for Covid-19 associated death, severity, and hospitalization versus lung cancer respectively. Hematologic cancer (OR 0.71, CI 0.56-0.90, *p* 0.005, I^2 68%), (OR 0.63, CI 0.47-0.83, *p* 0.001, I^2 46%), (OR 0.26, CI 0.10-0.67, *p* 0.005, I^2 0%) for Covid-19 infectivity, death, and severity respectively. The "*TERAVOLT*" study and the one conducted by *Luo et*

al. also support our finding of a high Covid-19 associated adverse outcomes among lung cancer patients.[70,71] Other meta-analyses show lung cancer with Covid-19 has a 32.9% case fatality rate (378 lung cancer), compared to the non-lung cancer population the Covid-19 death among lung cancer is also higher (92 lung cancer, 554 control, OR 1.83, *p* 0.05), (78 lung cancer, 482 control, RR 1.46, *p* 0.7).[5,63,64] Lastly, most studies also support our findings on the increased Covid-19 adverse outcome in the hematologic cancer population, as their results are 34.2% case fatality rate (480 hematologic cancer), (120 hematologic cancer, 758 control, OR 2.39, *p* 0.02).[63,64,66-69.] We believe our meta-analysis results correspond to several studies that present the safety of continuing gynecologic cancer care and service during the global pandemic. Safety protocols have been published for gynecologic cancer patients who are seeking treatment and some even recommend the implementation of ERAS (Enhanced Recovery After Surgery).[2,72,73] Data from the French Society for Pelvic and Gynecological Surgery (SCGP) and the French (FRANCOGYN) Group reveal there are changes in cancer management strategy during the pandemic time and from 181 gynecologic cancer patients, 8 tested positive of Covid-19.[74] Multicenter study from three New York City hospitals also show a similar result, among 302 gynecologic cancer patients, 117 experienced a COVID-19-related treatment modification, 19 have positive Covid-19 result among them 3 are asymptomatic, 11 are having mild symptoms, 3 are hospitalized, and 2 died.[75] Lastly, data from the United Kingdom, Turkey, and Italy show that while maintaining gynecologic cancer treatment during the pandemic time the Covid-19 infection rate is found at a low level, 1/289 is Covid-19 positive and 1 post-operative death suspected of Covid-19 (UK), 2/200 is suspected with Covid-19 but neither was positive for COVID-19 on polymerase chain reaction testing (Turkey), and 1/930 is Covid-19 positive (Italy).[76-78] Meta-analysis shows Covid-19 infection with existing comorbidities such as hypertension (OR 1.95, *p* <0.0001), diabetes (OR 1.97, *p* <0.0001), respiratory disease (OR 2.74, *p* <0.0001), cardiovascular disease (OR 3.05, *p* <0.0001), cerebrovascular disease (OR 4.78, *p* <0.0001), kidney disease (OR 4.90, *p* <0.0001), and cancer (OR 1.89, *p* <0.0001) increase the risk of mortality.[79] Our analyzed population comprises cancer as the main comorbidity, however with comorbidities other than cancer, our study shows that the gynecologic cancer population with additional comorbidities has fewer adverse events than other cancer with comorbidities (OR 0.31, CI 0.12-082, *p* 0.02, I^2 0%). Meta-analyses prove that men have increased Covid-19 severity and mortality.[79,80] Our findings correspond by showing that severity and hospitalization from Covid-19 were higher in men with cancer compared to gynecologic cancer patients (OR 0.47, CI 0.25-0.88, *p* 0.02, I^2 0%), (OR 0.71, CI 0.56-0.89, *p* 0.004, I^2 0%) respectively. Age thresholds above 50 and 60 years old have an effect on Covid-19 mortality.[79,81] In our study Covid-19 adverse outcome was lower in <65 years old gynecologic cancer than <65

years old other cancer patients (OR 0.16, CI 0.06-0.47, *p* 0.0007, I^2 0%). Meta-analysis on Covid-19 with active cancer treatment shows that cancer surgery (OR 1.14, *p* <0.01), chemotherapy (OR 1.60, <0.01), and overall cancer treatment type (OR 1.16, *p* <0.01) have a higher risk of death.[82] However in our study Covid-19 death is equivalent in gynecologic cancer with active cancer treatment compared to those who are not receiving cancer treatment (OR 1.06, CI 0.57-1.98, *p* 0.86, I^2 0%).

We hope these findings will be useful among gynecologist-oncologists in cancer centers or tertiary cancer referral centers who provide care to gynecologic cancer patients during the ongoing Covid-19 pandemic.

Limitations

In several data syntheses with the statistically nonsignificant value, we analyze few data regarding severity, hospitalization, age, cancer stage/metastatic status, other comorbidities aside from cancer, and cancer treatment type due to limited data, however those aforementioned are well represented and distributed through other synthesis based on the patient's characteristics available in **Table 1**.

Conflict of Interest

None declared.

Availability of data, code, and other materials

The report of the following are publicly available and they can be found in the supplementary material.

Figure 1. Study Flow Diagram.

Figure 2. Gynecologic cancer VS Other Cancer, Covid-19 Death.

Figure 3. Gynecologic cancer VS Non-Cancer, Covid-19 Death.

Figure 4. Gynecologic cancer with Covid-19 VS Other cancer non-covid, Covid-19 Death.

Figure 5. The covid-19 death, Gynecologic cancer with metastasis VS no metastasis.

Figure 6. Gynecologic cancer VS Lung Cancer, **(A)** Covid-19 death. **(B)** Severe Covid-19. **(C)** Covid-19 hospitalization.

Figure 7. Gynecologic cancer VS Breast Cancer, **(A)** Covid-19 death, **(B)** Covid-19 hospitalization.

Figure 8. Gynecologic cancer VS Hematologic Cancer, **(A)** Covid-19 infection. **(B)** Covid-19 death. **(C)** Severe Covid-19.

Figure 9. Gynecologic cancer patients VS Men with cancer. **(A)** Severe Covid-19, **(B)** Covid-19 hospitalization.

Figure 10. The covid-19 adverse outcome, <65 years old gynecologic cancer VS >65 years old other cancer population.

Figure 11. The covid-19 adverse outcome with comorbidities, Gynecologic cancer VS Other cancer.

REFERENCES

1. Ramirez PT, Chiva L,Eriksson AGZ, et al. COVID-19 Global Pandemic: Options for Management Gynecologic Cancers. Int J Gynecol Cancer 2020;0:1–3. doi:10.1136/ijgc-2020- 001419

2. Uwins C, Bhandoria GP, Shylasree TS, et al. Int J Gynecol Cancer 2020;30:1424–1433. doi:10.1136/ijgc-2020-001634

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249. https://doi.org/10.3322/caac.21660

4. Frey MK, Blank SV. Coronavirus Concerns: What do women with gynecologic cancer need to know during The Covid-19 crisis ? . Gynecologic Oncology. 2020; 158:32–33 . https://doi.org/10.1016/j.ygyno.2020.04.697

5. Han S, Zhuang Q, Chiang J, et al. Impact of cancer diagnoses on the outcomes of patients with COVID- 19: a systematic review and meta- analysis. BMJ Open 2022;0:e044661. doi:10.1136/bmjopen-2020-044661

6. G. M. ElGohary, S. Hashmi, J. Styczynski et al., The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis, Hematol Oncol Stem Cell Ther, https://doi.org/10.1016/j.hemonc.2020.07.005

7. Giannakoulis VG, Papoutsi E, Siempos I.I. Effect of Cancer on Clinical Outcomes of Patients With Covid-19 : A Meta-Analysis of Patient Data. JCO Global Oncology no. 6 (2020) 799-808. DOI: 10.1200/GO.20.00225

8. Choi JY, Smith DM. SARS-CoV-2 Variants of Concern. Yonsei Med J. 2021 Nov;62(11):961-968. https://doi.org/10.3349/ymj.2021.62.11.961

9. Minol. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions forMember States. 2021. https://doi.org/10.5281/zenodo.5744276

10. Page M J, McKenzie J E, Bossuyt P M, Boutron I, Hoffmann T C, Mulrow C D et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews *BMJ* 2021; 372 :n71 doi:10.1136/bmj.n71

11. Ma, LL., Wang, YY., Yang, ZH. *et al.* Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. *Military Med Res* 7, 7 (2020). https://doi.org/10.1186/s40779-020-00238-8

12. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.

13. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for*

Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.

14. Bauchner H, Golub RM, Zylke J. Editorial Concern-Possible Reporting of the Same Patients With COVID-19 in Different Reports. JAMA. 2020 Apr 7;323(13):1256. doi: 10.1001/jama.2020.3980. PMID: 32176775.

15. Angelis V, Tippu Z, Joshi K, et al. Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur J Cancer. 2020;136:99. doi:10.1016/J.EJCA.2020.06.027

16. Ayhan A, Oz M, Topfedaisi Ozkan N, et al. Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey. Gynecol Oncol. 2021;160(2):499-505. doi:10.1016/J.YGYNO.2020.11.014

17. Ayhan M, Laçin Ş, Özyükseler DT, et al. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021;27(6):1461-1467. doi:10.1177/10781552211015762

18. Ayhan M, Odabas H, Turan N, et al. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021;33(7):499-508. doi:10.1080/1120009X.2021.1923153

19. Basse C, Diakite S, Servois V, et al. Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. JNCI cancer Spectr. 2021;5(1). doi:10.1093/JNCICS/PKAA090

20. Bernard A, Cottenet J, Bonniaud P, et al. Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level. Cancers (Basel). 2021;13(6):1-15. doi:10.3390/CANCERS13061436

21. Bersanelli M, Giannarelli D, De Giorgi U, et al. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Ther Adv Med Oncol. 2020;12. doi:10.1177/1758835920968463

22. Bogani G, Ditto A, Bosio S, Brusadelli C, Raspagliesi F. Cancer patients affected by COVID-19: Experience from Milan, Lombardy. Gynecol Oncol. 2020;158(2):262-265. doi:10.1016/J.YGYNO.2020.06.161

23. Cavanna L, Citterio C, Di Nunzio C, et al. Prevalence of COVID-19 Infection in Asymptomatic Cancer Patients in a District With High Prevalence of SARS-CoV-2 in Italy. Cureus. 2021;13(3). doi:10.7759/CUREUS.13774

24. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783. doi:10.1158/2159-8290.CD-20-0422

25. De Melo AC, Thuler LCS, Da Silva JL, et al. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute. PLoS One. 2020;15(10). doi:10.1371/JOURNAL.PONE.0241261

26. Dettorre GM, Dolly S, Loizidou A, et al. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother cancer. 2021;9(3). doi:10.1136/JITC-2020-002277

27. Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC. Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil. Cancers (Basel). 2020;12(12):1-13. doi:10.3390/CANCERS12123490

28. Fernandes GA, Feriani D, França e Silva ILA, et al. Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center. Semin Oncol. 2021;48(2):171. doi:10.1053/J.SEMINONCOL.2021.01.003

29. Glasbey JC, Nepogodiev D, Simoes JFF, et al. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. J Clin Oncol. 2021;39(1):66-78. doi:10.1200/JCO.20.01933

30. Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(6):787-800. doi:10.1016/J.ANNONC.2021.02.024

31. Hathout L, Ennis RD, Mattes MD, et al. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience. Adv Radiat Oncol. 2021;6(1). doi:10.1016/J.ADRO.2020.10.013

32. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020;38(30):3538-3546. doi:10.1200/JCO.20.01307

33. Johannesen TB, Smeland S, Aaserud S, et al. COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway. Front Oncol. 2021;11. doi:10.3389/FONC.2021.652535

34. Kulle CB, Azamat IF, Vatansever D, et al. Is elective cancer surgery feasible during the lock-down period of the COVID-19 pandemic? Analysis of a single institutional experience of 404 consecutive patients. J Surg Oncol. 2021;123(7):1495-1503. doi:10.1002/JSO.26436

35. Kuru B, Kale A, Basol G, et al. Is it safe to perform elective gynaecologic surgery during the two peaks of COVID-19 pandemic? Int J Clin Pract. 2021;75(11). doi:10.1111/IJCP.14816

36. Lara OD, Smith M, Wang Y, et al. COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic. Gynecol Oncol. 2022;164(2):304-310. doi:10.1016/J.YGYNO.2021.12.004

37. Lee LYW, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). 2020;395(10241):1919-1926. doi:10.1016/S0140-6736(20)31173-9

38. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020;21. doi:10.1016/J.ECLINM.2020.100331

39. Li H, Baldwin E, Zhang X, et al. Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type. BMJ Heal care informatics. 2021;28(1). doi:10.1136/BMJHCI-2021-100341

40. Liang J, Jin G, Liu T, et al. Clinical characteristics and risk factors for mortality in cancer patients with COVID-19. Front Med. 2021;15(2):1. doi:10.1007/S11684-021-0845-6

41. Liu C, Li L, Song K, et al. A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study. J Immunother Cancer. 2020;8(2):e001314. doi:10.1136/JITC-2020-001314

42. Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10(7):935-941. doi:10.1158/2159-8290.CD-20-0516

43. Modi C, Dragun AE, Henson CF, et al. A Statewide Multi-Institutional Study of Asymptomatic Pretreatment Testing of Radiation Therapy Patients for SARS-CoV-2 in a High-Incidence Region of the United States. Adv Radiat Oncol. 2021;6(4). doi:10.1016/J.ADRO.2021.100704

44. Monroy-Iglesias MJ, Tagliabue M, Dickinson H, et al. Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan. Cancers (Basel). 2021;13(7). doi:10.3390/CANCERS13071597

45. Mousavi SA, Rostami T, Kiumarsi A, et al. COVID-19 and cancer: A comparative case series. Cancer Treat Res Commun. 2021;27:100339. doi:10.1016/J.CTARC.2021.100339

46. Nakamura, S., Kanemasa, Y., Atsuta, Y. *et al*. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. *Int J Clin Oncol* 26, 485–493 (2021). https://doi.org/10.1007/s10147-020-01837-0

47. Ning MS, McAleer MF, Jeter MD, et al. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol. 2020;148:252-257. doi:10.1016/J.RADONC.2020.05.037

48. Pinato DJ, Patel M, Scotti L, et al. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA Oncol. 2022;8(1):114-122. doi:10.1001/JAMAONCOL.2021.6199

49. Ramaswamy A, Nayak L, Roy Moulik N, et al. COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Med. 2020;9(23):8747-8753. doi:10.1002/CAM4.3423

50. Roel E, Pistillo A, Recalde M, et al. Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain. Int J cancer. 2022;150(5):782-794. doi:10.1002/IJC.33846

51. Russell B, Moss CL, Palmer K, et al. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. Cancers 2021, Vol 13, Page 2479. 2021;13(10):2479. doi:10.3390/CANCERS13102479

52. Song C, Dong Z, Gong H, et al. An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study. J Cancer Res Clin Oncol. 2021;147(4):1247-1257. doi:10.1007/S00432-020-03420-6

53. Song K, Gong H, Xu B, et al. Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study. Cancer. 2021;127(3):437-448. doi:10.1002/CNCR.33240

54. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893. doi:10.1016/S1470-2045(20)30309-0

55. Cabrera Villegas A, Romero Robles LG, Boulvard Chollet XLE, et al. [18 F]-FDG PET/CT in oncologic patients with unsuspected asymptomatic infection with SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2021;48(3):786-793. doi:10.1007/S00259-020-04979-5

56. Wang QQ, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021;7(2):220-227. doi:10.1001/JAMAONCOL.2020.6178

57. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92(10):2067-2073. doi:10.1002/JMV.25972

58. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904-913. doi:10.1016/S1470-2045(20)30310-7

59. Yang S, Zhang Y, Cai J, Wang Z. Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records. Oncologist. 2020;25(6):e982-e985. doi:10.1634/THEONCOLOGIST.2020-0157

60. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(7):894-901. doi:10.1016/J.ANNONC.2020.03.296

61. Zhou K, Blanc-Lapierre A, Seegers V, et al. Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort Study. Cancers (Basel). 2021;13(14). doi:10.3390/CANCERS13143389

62. Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1431-1437. doi:10.1016/J.DSX.2020.07.037

63. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus. JNCI Cancer Spectr. 2021;5(2). doi:10.1093/JNCICS/PKAA102

64. Zhang H, Han H, He T, et al. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2021;113(4):371-380. doi:10.1093/JNCI/DJAA168

65. Sorouri, M., Kasaeian, A., Mojtabavi, H. *et al*. Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study. *Infect Agents Cancer* 15, 74 (2020). https://doi.org/10.1186/s13027-020-00339-y

66. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol. 2022;8(1):69-78. doi:10.1001/jamaoncol.2021.5148

67. Sharafeldin N, Bates B, Song Q, et al. Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C). J Clin Oncol. 2021;39(20):2232-2246. doi:10.1200/JCO.21.01074

68. Albiges L, Foulon S, Bayle A, et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat Cancer. doi:10.1038/s43018-020-00120-5

69. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. doi:10.1016/S0140-6736(20)31187-9

70. Garassino MC, Whisenant JG, Huang L-C, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914-922. doi:10.1016/S1470-2045(20)30314-4

71. Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(10):1386-1396. doi:10.1016/j.annonc.2020.06.007

72. Thomakos N, Pandraklakis A, Bisch SP, Rodolakis A, Nelson G. ERAS protocols in gynecologic oncology during COVID-19 pandemic. Int J Gynecol Cancer. 2020;30(6):ijgc-2020-001439. doi:10.1136/IJGC-2020-001439

73. Bisch SP, Jago CA, Kalogera E, et al. Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis. Gynecol Oncol. 2021;161(1):46-55. doi:10.1016/J.YGYNO.2020.12.035

74. Jouen T, Gauthier T, Azais H, et al. The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group. J Gynecol Obstet Hum Reprod. 2021;50(8). doi:10.1016/J.JOGOH.2021.102133

75. Frey MK, Fowlkes RK, Badiner NM, et al. Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020;159(2):470-475. doi:10.1016/J.YGYNO.2020.09.005

76. Leung E, Pervaiz Z, Lowe-Zinola J, et al. Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre. Gynecol Oncol. 2021;160(3):649-654. doi:10.1016/J.YGYNO.2020.12.013

77. Dursun P, Dervisoglu H, Daggez M, et al. Performing gynecologic cancer surgery during the COVID-19 pandemic in Turkey: A multicenter retrospective obser

78. Palluzzi E, Corrado G, Marchetti C, et al. Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic. Int J Gynecol Cancer. 2021;31(8):1154-1158. doi:10.1136/IJGC-2020-002288

79. Biswas M, Rahaman S, Biswas T, K, Haque Z, Ibrahim B: Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology 2021;64:36-47. doi: 10.1159/000512592

80. Peckham, H., de Gruijter, N.M., Raine, C. *et al*. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nat Commun* 11, 6317 (2020). https://doi.org/10.1038/s41467-020-19741-6

81. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020;21(7):915-918. doi:10.1016/J.JAMDA.2020.05.045

82. Park R, Lee SA, Kim SY, de Melo AC, Kasi A. Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol (Madr). 2021;60(1):13-19. https://doi.org/10.1080/0284186X.2020.1837946

Figure 1. Study Flow Diagram.



Figure 2. Gynecologic cancer VS Other Cancer, Covid-19 Death.

Study or Subgroup	Gyn-Onco Covid Events	Gyn-Onco Covid Total	Other Cancer Events	Other Cancer Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan M et al (2).	2	7	20	85	0.7%	1.30 [0.23, 7.22]
Basse C et al.	2	12	24	129	0.8%	0.88 [0.18, 4.25]
Bernard A et al.	54	185	1799	5537	19.1%	0.86 [0.62, 1.18]
Chai C et al	1	16	33	150	0.5%	0.24 [0.03, 1.86]
Dai M et al.	0	8	12	97	0.2%	0.40 [0.02, 7.41]
de Melo AC et al.	6	22	54	159	2.0%	0.73 [0.27, 1.97]
Dettorre G et al.	21	57	354	1014	6.5%	1.09 [0.63, 1.89]
Duarte M et al.	55	75	387	606	6.8%	1.56 [0.91, 2.66]
Fang M et al.	0	4	12	52	0.2%	0.36 [0.02, 7.16]
Fernandes G et al.	2	26	49	385	0.9%	0.57 [0.13, 2.49]
Grivas P et al.	37	322	690	4796	16.0%	0.77 [0.54, 1.10]
Jee J et al.	1	15	52	294	0.5%	0.33 [0.04, 2.58]
Lee L et al.	5	45	221	755	2.2%	0.30 [0.12, 0.78]
Lei S et al.	0	1	4	8	0.2%	0.33 [0.01, 10.57]
Liang J et al.	2	10	21	99	0.8%	0.93 [0.18, 4.70]
Li H et al.	5	17	59	272	1.7%	1.50 [0.51, 4.44]
Liu C et al.	1	17	36	199	0.5%	0.28 [0.04, 2.20]
Mehta V et al.	4	12	57	206	1.3%	1.31 [0.38, 4.51]
Mousavi S et al.	2	3	14	30	0.3%	2.29 [0.19, 27.99]
Nakamura S et al	0	1	11	31	0.2%	0.59 [0.02, 15.81]
OnCovid Study Group.	24	115	555	2413	9.4%	0.88 [0.56, 1.40]
Roel E at al.	61	436	976	4957	25.3%	0.66 [0.50, 0.88]
Shi Z et al.	4	9	83	409	1.1%	3.14 [0.83, 11.96]
Song C et al.	0	17	37	206	0.2%	0.13 [0.01, 2.20]
Song K et al.	2	10	38	238	0.8%	1.32 [0.27, 6.44]
Tian J et al.	2	15	44	217	0.8%	0.60 [0.13, 2.78]
Villegas A et al.	0	1	2	6	0.2%	0.60 [0.02, 20.98]
Yang F et al.	2	6	9	46	0.6%	2.06 [0.32, 13.03]
Yang K et al.	0	9	28	142	0.2%	0.21 [0.01, 3.74]
Zhang L et al.	0	3	8	25	0.2%	0.29 [0.01, 6.36]
Total (95% CI)		**1476**		**23563**	**100.0%**	**0.82 [0.71, 0.94]**
Total events	295		5689			

Heterogeneity: Tau² = 0.00; Chi² = 28.75, df = 29 (P = 0.48); I² = 0%

Test for overall effect: Z = 2.76 (P = 0.006)



Figure 3. Gynecologic cancer VS Non-Cancer, Covid-19 Death.

Study or Subgroup	Gyn-Onco Covid Events	Total	Non Cancer Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan M et al (2).	2	7	141	2289	2.9%	6.09 [1.17, 31.69]
Bernard A et al.	54	185	13057	83329	27.2%	2.22 [1.61, 3.05]
Chai C et.al	1	16	42	498	1.9%	0.72 [0.09, 5.62]
Dai M et al.	0	8	13	105	1.0%	0.40 [0.02, 7.39]
Duarte M et al.	55	75	14255	38468	17.9%	4.67 [2.80, 7.80]
Lei S et al.	0	1	3	25	0.7%	2.14 [0.07, 63.76]
Li H et al.	5	17	44	275	6.0%	2.19 [0.73, 6.52]
Mehta V et al.	4	12	149	1090	5.0%	3.16 [0.94, 10.62]
Roel E at al.	61	436	4203	93558	29.8%	3.46 [2.63, 4.54]
Shi Z et al.	4	9	160	1306	4.3%	5.73 [1.52, 21.56]
Tian J et al.	2	15	56	519	3.4%	1.27 [0.28, 5.78]
Total (95% CI)		**781**		**221462**	**100.0%**	**2.98 [2.23, 3.98]**
Total events	188		32123			

Heterogeneity: Tau² = 0.05; Chi² = 14.33, df = 10 (P = 0.16); I² = 30%

Test for overall effect: Z = 7.38 (P < 0.00001)



Figure 4. Gynecologic cancer with Covid-19 VS Other cancer non-covid, Covid-19 Death.

Study or Subgroup	Gyn-Onco Covid Events	Total	Non Covid Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan A et al (3).	0	46	3	642	1.5%	1.96 [0.10, 38.61]
Chai C et.al	1	16	8	498	2.9%	4.08 [0.48, 34.75]
Li H et al.	5	17	143	4161	11.2%	11.71 [4.07, 33.67]
Monroy-Iglesias MJ et al.	1	2	38	3014	1.7%	78.32 [4.81, 1275.34]
Roel E at al.	61	436	3356	255274	82.7%	12.21 [9.30, 16.04]
Total (95% CI)		**517**		**263589**	**100.0%**	**11.83 [8.20, 17.07]**
Total events	68		3548			

Heterogeneity: Tau² = 0.02; Chi² = 4.22, df = 4 (P = 0.38); I² = 5%

Test for overall effect: Z = 13.20 (P < 0.00001)



Figure 5. The covid-19 death, Gynecologic cancer with metastasis VS no metastasis.

Study or Subgroup	Gyn-Onco Metastasis Events	Total	Localized Cancer Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Bernard A et al.	41	119	690	2558	89.9%	1.42 [0.97, 2.10]
de Melo AC et al.	5	13	17	91	8.9%	2.72 [0.79, 9.36]
Li H et al.	3	7	0	3	1.3%	5.44 [0.21, 144.10]
Total (95% CI)		**139**		**2652**	**100.0%**	**1.53 [1.06, 2.21]**
Total events	49		707			

Heterogeneity: Tau² = 0.00; Chi² = 1.54, df = 2 (P = 0.46); I² = 0%

Test for overall effect: Z = 2.28 (P = 0.02)



Figure 6 A. Gynecologic cancer VS Lung Cancer, covid-19 death.

Study or Subgroup	Gyn-Onco Covid Events	Gyn-Onco Covid Total	Lung Cancer Events	Lung Cancer Total	Weight	Odds Ratio M-H, Random, 95% CI
Angelis V et al.	1	6	4	15	0.5%	0.55 [0.05, 6.27]
Ayhan M et al (2).	2	7	4	26	0.8%	2.20 [0.31, 15.55]
Basse C et al.	2	12	6	18	0.9%	0.40 [0.07, 2.44]
Bernard A et al.	54	185	359	873	25.5%	0.59 [0.42, 0.83]
Bersanelli M et al.	0	1	7	9	0.2%	0.11 [0.00, 3.70]
Chai C et al	1	16	4	25	0.6%	0.35 [0.04, 3.45]
Dai M et al.	0	8	4	22	0.3%	0.24 [0.01, 5.02]
de Melo AC et al.	6	22	4	7	1.0%	0.28 [0.05, 1.65]
Dettorre G et al.	21	57	73	154	7.8%	0.65 [0.35, 1.21]
Duarte M et al.	55	75	38	51	4.6%	0.94 [0.42, 2.12]
Fang M et al.	0	4	2	9	0.3%	0.33 [0.01, 8.63]
Fernandes G et al.	2	26	6	18	1.0%	0.17 [0.03, 0.95]
Grivas P et al.	37	322	107	409	18.3%	0.37 [0.24, 0.55]
Jee J et al.	1	15	11	29	0.6%	0.12 [0.01, 1.02]
Lee L et al.	5	45	32	90	2.9%	0.23 [0.08, 0.63]
Liang J et al.	2	10	2	14	0.7%	1.50 [0.17, 12.94]
Li H et al.	5	17	7	18	1.5%	0.65 [0.16, 2.68]
Liu C et al.	1	17	14	49	0.7%	0.16 [0.02, 1.29]
Mehta V et al.	4	12	6	11	1.1%	0.42 [0.08, 2.25]
Mousavi S et al.	2	3	2	4	0.3%	2.00 [0.09, 44.35]
Nakamura S et al	0	1	1	2	0.2%	0.33 [0.01, 16.80]
OnCovid Study Group.	24	115	119	355	12.1%	0.52 [0.32, 0.86]
Ramaswamy A et al.	2	13	2	12	0.7%	0.91 [0.11, 7.72]
Roel E at al.	61	436	32	159	13.6%	0.65 [0.40, 1.04]
Shi Z et al.	4	9	1	10	0.5%	7.20 [0.62, 83.34]
Song C et al.	0	17	8	39	0.4%	0.11 [0.01, 1.95]
Song K et al.	2	10	16	61	1.1%	0.70 [0.13, 3.67]
Tian J et al.	2	15	9	23	1.0%	0.24 [0.04, 1.32]
Yang F et al.	2	6	2	10	0.6%	2.00 [0.20, 19.91]
Yang K et al.	0	9	6	24	0.3%	0.15 [0.01, 2.95]
Total (95% CI)		**1491**		**2546**	**100.0%**	**0.52 [0.44, 0.62]**
Total events	298		888			

Heterogeneity: Tau² = 0.00; Chi² = 28.44, df = 29 (P = 0.49); I² = 0%

Test for overall effect: Z = 7.31 (P < 0.00001)



Figure 6B. Gynecologic cancer VS Lung Cancer, severe Covid-19.

Study or Subgroup	Gyn-Onco Covid Events	Total	Lung Cancer Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Dai M et al.	2	8	12	22	19.4%	0.28 [0.05, 1.69]
de Melo AC et al.	3	22	0	7	6.7%	2.69 [0.12, 58.61]
Jee J et al.	1	15	6	29	12.9%	0.27 [0.03, 2.52]
Song K et al.	2	10	21	61	23.6%	0.48 [0.09, 2.45]
Tian J et al.	8	15	18	23	31.5%	0.32 [0.08, 1.31]
Zhang L et al.	0	3	4	7	5.9%	0.11 [0.00, 2.94]
Total (95% CI)		**73**		**149**	**100.0%**	**0.36 [0.16, 0.80]**
Total events	16		61			

Heterogeneity: Tau² = 0.00; Chi² = 2.42, df = 5 (P = 0.79); I² = 0%

Test for overall effect: Z = 2.50 (P = 0.01)



Figure 6C. Gynecologic cancer VS Lung Cancer, covid-19 hospitalization.

Study or Subgroup	Gyn-Onco Covid Events	Gyn-Onco Covid Total	Lung Cancer Events	Lung Cancer Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan M et al (1).	3	4	25	27	1.3%	0.24 [0.02, 3.51]
Grivas P et al.	178	322	284	409	98.7%	0.54 [0.40, 0.74]
Total (95% CI)		**326**		**436**	**100.0%**	**0.54 [0.40, 0.73]**
Total events	181		309			

Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 1 (P = 0.55); I² = 0%

Test for overall effect: Z = 4.01 (P < 0.0001)



Figure 7A. Gynecologic cancer VS Breast Cancer, covid-19 death.

Study or Subgroup	Gyn-Onco Covid Events	Gyn-Onco Covid Total	Breast Cancer Events	Breast Cancer Total	Weight	Odds Ratio M-H, Random, 95% CI
Angelis V et al.	1	6	2	18	0.7%	1.60 [0.12, 21.59]
Ayhan M et al (2).	2	7	2	17	1.0%	3.00 [0.33, 27.23]
Basse C et al.	2	12	5	57	1.5%	2.08 [0.35, 12.26]
Bernard A et al.	54	185	133	561	15.5%	1.33 [0.91, 1.92]
Chai C et.al	1	16	2	19	0.8%	0.57 [0.05, 6.90]
de Melo AC et al.	6	22	21	40	3.5%	0.34 [0.11, 1.04]
Dettorre G et al.	21	57	37	177	8.3%	2.21 [1.15, 4.22]
Duarte M et al.	55	75	51	90	8.1%	2.10 [1.09, 4.07]
Fernandes G et al.	2	26	8	93	1.8%	0.89 [0.18, 4.45]
Grivas P et al.	37	322	82	967	14.2%	1.40 [0.93, 2.11]
Jee J et al.	1	15	6	56	1.0%	0.60 [0.07, 5.36]
Lee L et al.	5	45	18	102	3.8%	0.58 [0.20, 1.68]
Liang J et al.	2	10	0	11	0.5%	6.76 [0.29, 159.95]
Li H et al.	5	17	2	42	1.5%	8.33 [1.43, 48.54]
Liu C et al.	1	17	1	34	0.6%	2.06 [0.12, 35.14]
Mehta V et al.	4	12	5	29	2.0%	2.40 [0.51, 11.19]
Mousavi S et al.	2	3	3	6	0.6%	2.00 [0.11, 35.81]
OnCovid Study Group.	24	115	55	448	10.7%	1.88 [1.11, 3.20]
Ramaswamy A et al.	2	13	3	30	1.3%	1.64 [0.24, 11.18]
Roel E at al.	61	436	142	1236	17.3%	1.25 [0.91, 1.73]
Shi Z et al.	4	9	2	47	1.3%	18.00 [2.61, 124.33]
Song K et al.	2	10	2	37	1.1%	4.38 [0.53, 35.91]
Tian J et al.	2	15	5	31	1.5%	0.80 [0.14, 4.70]
Yang F et al.	2	6	2	9	0.9%	1.75 [0.17, 17.69]
Yang K et al.	0	9	3	40	0.5%	0.56 [0.03, 11.88]
Total (95% CI)		**1460**		**4197**	**100.0%**	**1.50 [1.20, 1.88]**
Total events	298		592			

Heterogeneity: Tau² = 0.05; Chi² = 29.81, df = 24 (P = 0.19); I² = 19%

Test for overall effect: Z = 3.54 (P = 0.0004)



Figure 7B. Gynecologic cancer VS Breast Cancer, covid-19 hospitalization.

Study or Subgroup	Gyn-Onco Covid Events	Total	Breast Cancer Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan M et al (1).	3	4	13	18	1.0%	1.15 [0.10, 13.88]
Grivas P et al.	178	322	433	967	99.0%	1.52 [1.18, 1.96]
Total (95% CI)		**326**		**985**	**100.0%**	**1.52 [1.18, 1.96]**
Total events	181		446			

Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.83); I² = 0%

Test for overall effect: Z = 3.25 (P = 0.001)



Figure 8A. Gynecologic cancer VS Hematologic Cancer, covid-19 infection.

Study or Subgroup	Gyn-Onco Events	Gyn-Onco Total	Hemato-Onco Events	Hemato-Onco Total	Weight	Odds Ratio M-H, Random, 95% CI
Angelis V et al.	6	973	18	1085	5.3%	0.37 [0.15, 0.93]
Johannesen T et al.	33	23860	54	25667	13.4%	0.66 [0.43, 1.01]
Kwon D et al.	119	2996	321	5937	19.9%	0.72 [0.58, 0.90]
Li H et al.	17	239	53	681	10.2%	0.91 [0.51, 1.60]
Roel E at al.	436	19897	513	21637	22.1%	0.92 [0.81, 1.05]
Russell B et al.	10	226	33	195	7.4%	0.23 [0.11, 0.47]
Shi Z et al.	9	68	49	237	6.9%	0.59 [0.27, 1.26]
Wang Q et al.	30	41740	220	306640	14.8%	1.00 [0.68, 1.47]
Total (95% CI)		**89999**		**362079**	**100.0%**	**0.71 [0.56, 0.90]**
Total events	660		1261			

Heterogeneity: Tau² = 0.06; Chi² = 21.95, df = 7 (P = 0.003); I² = 68%

Test for overall effect: Z = 2.82 (P = 0.005)



Figure 8B. Gynecologic cancer VS Hematologic Cancer, covid-19 death.

Study or Subgroup	Gyn-Onco Covid Events	Total	Hemato-Onco Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Angelis V et al.	1	6	11	18	1.3%	0.13 [0.01, 1.33]
Basse C et al.	2	12	5	19	2.1%	0.56 [0.09, 3.49]
Bernard A et al.	54	185	470	1389	11.8%	0.81 [0.58, 1.13]
Chai C et.al	1	16	8	17	1.5%	0.07 [0.01, 0.70]
Dai M et al.	0	8	3	8	0.8%	0.09 [0.00, 2.16]
de Melo AC et al.	6	22	8	34	3.9%	1.22 [0.36, 4.16]
Dettorre G et al.	21	57	29	87	7.6%	1.17 [0.58, 2.35]
Duarte M et al.	55	75	96	155	8.6%	1.69 [0.92, 3.10]
Fang M et al.	0	4	5	10	0.8%	0.11 [0.00, 2.60]
Fernandes G et al.	2	26	10	47	2.6%	0.31 [0.06, 1.53]
Grivas P et al.	37	322	191	1097	11.3%	0.62 [0.42, 0.90]
Jee J et al.	1	15	18	71	1.6%	0.21 [0.03, 1.71]
Lee L et al.	5	45	60	169	5.3%	0.23 [0.09, 0.61]
Liang J et al.	2	10	5	12	1.9%	0.35 [0.05, 2.41]
Li H et al.	5	17	23	53	4.1%	0.54 [0.17, 1.76]
Mehta V et al.	4	12	40	108	3.7%	0.85 [0.24, 3.00]
Nakamura S et.al	0	1	3	7	0.6%	0.43 [0.01, 14.08]
OnCovid Study Group.	24	115	79	343	9.6%	0.88 [0.53, 1.48]
Ramaswamy A et al.	2	13	8	90	2.4%	1.86 [0.35, 9.92]
Roel E at al.	61	436	117	513	11.7%	0.55 [0.39, 0.77]
Shi Z et al.	4	9	20	49	3.1%	1.16 [0.28, 4.86]
Song C et al.	0	17	8	15	0.9%	0.03 [0.00, 0.50]
Tian J et al.	2	15	5	12	2.0%	0.22 [0.03, 1.41]
Yang K et al.	0	9	9	22	0.9%	0.07 [0.00, 1.45]
Total (95% CI)		**1447**		**4345**	**100.0%**	**0.63 [0.47, 0.83]**
Total events	289		1231			

Heterogeneity: Tau² = 0.15; Chi² = 42.32, df = 23 (P = 0.008); I² = 46%

Test for overall effect: Z = 3.20 (P = 0.001)



Figure 8C. Gynecologic cancer VS Hematologic Cancer, severe Covid-19.

Study or Subgroup	Gyn-Onco Covid Events	Total	Hemato-Onco Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Dai M et al.	2	8	4	8	19.8%	0.33 [0.04, 2.77]
de Melo AC et al.	3	22	9	34	42.9%	0.44 [0.10, 1.84]
Jee J et al.	1	15	23	71	20.3%	0.15 [0.02, 1.20]
Tian J et al.	8	15	11	12	17.0%	0.10 [0.01, 1.02]
Total (95% CI)		**60**		**125**	**100.0%**	**0.26 [0.10, 0.67]**
Total events	14		47			

Heterogeneity: Tau² = 0.00; Chi² = 1.48, df = 3 (P = 0.69); I² = 0%

Test for overall effect: Z = 2.79 (P = 0.005)



Figure 9A. Gynecologic cancer patients VS Men with cancer, severe Covid-19.

Study or Subgroup	Gyn-Onco Covid Events	Gyn-Onco Covid Total	Cancer Men Events	Cancer Men Total	Weight	Odds Ratio M-H, Random, 95% CI
Dai M et al.	2	8	22	59	14.1%	0.56 [0.10, 3.02]
de Melo AC et al.	3	22	19	70	22.8%	0.42 [0.11, 1.60]
Jee J et al.	1	15	37	159	9.4%	0.24 [0.03, 1.85]
Song K et al.	2	10	30	128	15.6%	0.82 [0.16, 4.06]
Tian J et al.	8	15	81	119	34.0%	0.54 [0.18, 1.59]
Zhang L et al.	0	3	11	17	4.1%	0.08 [0.00, 1.82]
Total (95% CI)		**73**		**552**	**100.0%**	**0.47 [0.25, 0.88]**
Total events	16		200			

Heterogeneity: Tau² = 0.00; Chi² = 2.28, df = 5 (P = 0.81); I² = 0%

Test for overall effect: Z = 2.36 (P = 0.02)



Figure 9B. Gynecologic cancer patients VS Men with cancer, covid-19 hospitalization.

Study or Subgroup	Gyn-Onco Events	Gyn-Onco Total	Cancer Men Events	Cancer Men Total	Weight	Odds Ratio M-H, Random, 95% CI
Ayhan M et al (1).	3	4	45	50	0.9%	0.33 [0.03, 3.84]
Grivas P et al.	178	322	1546	2436	99.1%	0.71 [0.56, 0.90]
Total (95% CI)		**326**		**2486**	**100.0%**	**0.71 [0.56, 0.89]**
Total events	181		1591			

Heterogeneity: Tau² = 0.00; Chi² = 0.37, df = 1 (P = 0.54); I² = 0%

Test for overall effect: Z = 2.91 (P = 0.004)



Figure 10. Covid-19 adverse outcome, <65 years old gynecologic cancer VS >65 years old other cancer population.

Study or Subgroup	Gyn-Onco <65 Events	Total	Other Cancer >65 Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
Dai M et al.	2	7	35	50	36.4%	0.17 [0.03, 0.98]
de Melo AC et al.	3	11	37	53	52.8%	0.16 [0.04, 0.69]
Zhang L et al.	0	2	9	15	10.9%	0.14 [0.01, 3.34]
Total (95% CI)		**20**		**118**	**100.0%**	**0.16 [0.06, 0.47]**
Total events	5		81			

Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 2 (P = 0.99); I² = 0%

Test for overall effect: Z = 3.38 (P = 0.0007)



Figure 11. Covid-19 adverse outcome with comorbidities, Gynecologic cancer VS Other cancer.

Study or Subgroup	Gyn-Onco Events	Gyn-Onco Total	Other Cancer Events	Other Cancer Total	Weight	Odds Ratio M-H, Random, 95% CI
Bersanelli M et al.	0	1	7	8	7.2%	0.07 [0.00, 2.56]
Dai M et al.	1	2	36	56	12.0%	0.56 [0.03, 9.37]
de Melo AC et al.	5	15	55	95	72.9%	0.36 [0.12, 1.15]
Zhang L et al.	0	1	7	9	7.8%	0.11 [0.00, 3.70]
Total (95% CI)		**19**		**168**	**100.0%**	**0.31 [0.12, 0.82]**
Total events	6		105			

Heterogeneity: Tau² = 0.00; Chi² = 1.25, df = 3 (P = 0.74); I² = 0%

Test for overall effect: Z = 2.35 (P = 0.02)